Related by context. All words. (Click for frequent words.) 73 pharmacokinetics pharmacodynamics 73 safety tolerability pharmacokinetics 73 pharmacodynamic markers 72 safety tolerability pharmacokinetic 71 pharmacokinetics PK 70 pharmacodynamic profile 69 pharmacodynamic PD 69 novel VDA molecule 69 pharmacodynamic effects 69 neratinib 69 velafermin 68 blinded randomized placebo controlled 68 orally inhaled migraine 68 davunetide intranasal AL 68 pharmacodynamic profiles 68 pain palliation 68 CYT# potent vascular disrupting 68 phase Ib 68 multicenter Phase II 68 relapsed MM 67 label dose escalation 67 efficacy tolerability 67 INSPIRE Trial Phase III 67 oral deforolimus 67 preclinical efficacy 67 AKT inhibitor 67 analgesic efficacy 67 safety tolerability 67 galiximab 67 AAG geldanamycin analog 67 pharmacodynamic properties 67 EGFR HER2 67 Pharmacokinetics PK 67 SCH # 67 oral prodrug 67 ascending dose 67 pharmacodynamics 67 RE SURGE 66 DermaVir Patch 66 HGS ETR2 66 evaluating tivozanib 66 pharmacokinetic PK 66 riociguat 66 Azedra 66 PSMA ADC 66 antiangiogenic agents 66 pharmacokinetic parameters 66 MGd 66 NP2 Enkephalin 66 HCV NS5B polymerase 66 HuMax EGFr 66 Phase Ib clinical 66 MAGE A3 ASCI 66 pharmacodynamic parameters 66 HGS ETR1 mapatumumab 66 Prospective Randomized 66 prospective randomized multicenter 66 Randomized Double blind 66 urate lowering 66 Exelixis compounds 66 safety tolerability pharmacodynamics 66 investigational humanized monoclonal antibody 65 prokinetic agent 65 investigational monoclonal antibody 65 Bayer HealthCare Onyx Pharmaceuticals 65 erlotinib Tarceva ® 65 randomized multicenter trial 65 alvespimycin 65 GAMMAGARD 65 familial amyloidotic polyneuropathy FAP 65 GERD migraine headaches 65 elotuzumab 65 FOLOTYN ® 65 toenail onychomycosis 65 mertansine 65 histone deacetylase inhibitor 65 nab paclitaxel 65 Teriflunomide 65 Cardiotoxicity 65 Safinamide 65 IAP inhibitor 65 Afatinib 65 Hsp# Inhibitor 65 sorafenib tablets 65 LUX Lung 65 viral kinetics 65 sulodexide 65 pharmacokinetics 65 Phase Ib clinical trials 65 depsipeptide 65 interferon gamma 1b 65 sarcoma melanoma 65 Trandolapril 65 lexidronam injection 65 liposomal formulation 65 NATRECOR ® 64 pharmacodynamics PD 64 STRIDE PD 64 sunitinib malate 64 active comparator 64 Phase IIb III 64 pharmacodynamic endpoints 64 placebo controlled clinical 64 CBLC# 64 CIMZIA TM certolizumab pegol 64 pertuzumab 64 bevacizumab Avastin ® 64 vapreotide acetate 64 ZACTIMA 64 ritonavir boosted 64 Phase Ib II 64 HIF PH inhibitors 64 bazedoxifene conjugated estrogens 64 CR# vcMMAE 64 demonstrated antitumor activity 64 Sapacitabine 64 CTAP# Capsules 64 enzastaurin 64 phase IIb study 64 By JENNIFER LEARN 64 antiviral efficacy 64 Pharmacodynamic 64 registrational Phase 64 kidney urologic 64 ChronVac C R 64 MEK inhibitor RDEA# 64 TO AVOID PREGNANCY WHILE 64 EXPLORE Xa 64 PXD# 64 myelofibrosis polycythemia vera 64 NS5B polymerase 64 mapatumumab 64 Deforolimus 64 thetreatment 64 chronic thromboembolic pulmonary 64 Golimumab 64 Oral NKTR 64 ACTEMRA TM 64 cannabinor 64 multicenter Phase III 64 limiting toxicity DLT 64 AEG# 64 RG# ITMN 64 investigational hepatitis C 64 unique alkylating agent 64 plus Copegus R 64 Initiated Phase 64 pharmacokinetic equivalence 64 liposomal doxorubicin 64 cisplatin gemcitabine 64 EOquin TM phase 64 Prostate AdenoCarcinoma Treatment 64 Ceplene/IL-2 64 cilengitide 64 vorinostat 64 tolerability profiles 64 direct thrombin inhibitors 64 fosbretabulin 64 trastuzumab emtansine T DM1 64 LymphoStat B belimumab 64 OMP #M# 64 Traficet EN 64 p# biomarker 64 Archexin 64 PEGylated interferon beta 1a 64 multicenter randomized placebo controlled 63 docetaxel Taxotere R 63 Non inferiority 63 Initiates Phase II 63 Oral Fingolimod 63 pharmacokinetic PK profile 63 MGN# 63 postmenopausal osteoporotic women 63 recurrent glioblastoma multiforme 63 Phase Ib study 63 Pemetrexed 63 transthyretin TTR mediated amyloidosis 63 RELOVAIR ™ 63 vinca alkaloid 63 thorough QT 63 tanespimycin 63 favorable pharmacokinetic profile 63 AEGR 63 adecatumumab MT# 63 Initiate Phase 63 controlled multicenter Phase 63 metastatic pancreatic 63 Zemplar Capsules 63 novel emulsion formulation 63 recurrent metastatic ovarian cancer 63 RG# synthetic human 63 Tasimelteon 63 Preclinical studies suggest 63 fallopian tube cancers 63 virus HCV protease inhibitor 63 Vidaza azacitidine 63 Mg Usa 63 PI3K/Akt pathway inhibitor 63 Pertuzumab 63 sorafenib Nexavar ® 63 pharmacokinetic pharmacodynamic 63 plasma pharmacokinetics 63 FOLFOX6 chemotherapy regimen 63 BRIM2 63 oral mTOR inhibitor 63 samarium Sm 63 TNF Tumor Necrosis Factor 63 teriflunomide 63 sorafenib Nexavar 63 Zalypsis 63 refractory chronic lymphocytic 63 preclinical pharmacokinetic 63 Rigel R# 63 Meets Primary Endpoint 63 tolerated dose MTD 63 Panzem R NCD 63 serum biomarkers 63 CINQUIL 63 Randomized Phase 63 dose escalation clinical 63 Carfilzomib 63 morphometric vertebral fractures 63 CIMZIA ™ 63 IMC A# 63 mTOR inhibition 63 nucleotide analog 63 Phase #/#a 63 IMPACT DCM 63 metaglidasen 63 Initiates Clinical Trial 63 pathophysiological effects 63 ON #.Na 63 cariprazine 63 radiolabeled TM# 63 BEXXAR Therapeutic Regimen 63 dose proportionality 63 Multiple Ascending Dose 63 CEQ# 63 acetonide FA 63 bevacizumab Avastin R 63 biodistribution 63 5 fluorouracil leucovorin 63 BrachySil 63 Platinol ® cisplatin 63 huN# DM1 63 ara C 63 pregabalin Lyrica 63 anti amnesic 63 hemostatic efficacy 63 recurrent malignant gliomas 63 Randomized controlled 63 Primary endpoints 63 trial evaluating PRX# 63 Tumor Response 63 either acutely decompensated 63 phase IIb trial 63 dirucotide MBP# 62 unresectable tumors 62 gefitinib Iressa 62 Vascugel ® 62 R roscovitine 62 Completes Patient Enrollment 62 fusion enhancers 62 CLORETAZINE TM VNP#M 62 lead Aganocide compound 62 Xanafide 62 complement inhibitor eculizumab 62 trastuzumab Herceptin R 62 constipation OIC 62 gemcitabine Gemzar ® 62 CG# [003] 62 ascending dose study 62 Hormone Refractory Prostate Cancer 62 intravesical infusion therapy 62 non nucleoside 62 pharmacodynamic 62 pramlintide metreleptin combination 62 aerosolized KL4 surfactant 62 EXPAREL ™ 62 randomized discontinuation trial 62 desvenlafaxine succinate 62 hypoxia activated prodrug 62 tolerability 62 IRX 2 62 evaluating satraplatin 62 Solorel TM 62 GI motility disorders 62 LHRH antagonists 62 proton MR spectroscopy 62 CCR5 mAb 62 crizotinib PF # 62 DAVANAT 62 placebo controlled dose escalation 62 randomized controlled Phase 62 HER2 positive metastatic breast 62 dasatinib Sprycel ® 62 5 FU leucovorin 62 double blinded placebo 62 Enzastaurin 62 ALN HPN 62 radiation dosimetry 62 Vidaza ® 62 itraconazole Sporanox 62 topically administered 62 FUSILEV enhances 62 HGS ETR1 62 Antisoma AS# 62 GRNCM1 62 oral rivaroxaban 62 biologic DMARD 62 forodesine 62 antitumor efficacy 62 Liposomal 62 TKB# 62 Vaxfectin TM 62 Dual Opioid 62 subcutaneous SC 62 subcutaneous PRO 62 pharmacokinetic PK study 62 Phase IIb clinical trials 62 delay bone metastases 62 randomized blinded 62 prostate cancer PCa 62 Ophena TM 62 Obatoclax 62 Degarelix 62 PKC# 62 baminercept 62 GW# [003] 62 standard chemotherapy regimen 62 ZYBRESTAT fosbretabulin 62 deCODE AF TM 62 ALA PDT 62 REVIVE Diabetes 62 solithromycin 62 Maximum Tolerated Dose MTD 62 LEP ETU 62 GOUT 62 FOLFOX6 62 targeting miR 62 PREZISTA r 62 KRN# 62 double blinded randomized 62 urinary N telopeptide 62 CorVue ™ 62 systemically administered 62 vidofludimus 62 ALN TTR 62 MORAb 62 TAXUS VI 62 BRAF inhibitor 62 velafermin belinostat 62 Crofelemer budesonide foam 62 Phase 1b clinical trials 62 CANCIDAS 62 gemcitabine cisplatin 62 endothelin antagonists 62 Glufosfamide 62 preclinically 62 2 inhibitor CYT# 62 Aflibercept 62 hA# 62 evaluating REVLIMID 62 induced mucositis 62 Cloretazine 62 ZK EPO 62 JAK inhibitor 62 pharmacokinetic profiles 62 romidepsin 62 Novel Oral 62 refractory CLL 62 Androxal TM 62 cediranib 62 monoclonal antibody IgG1 Mab 62 relapsing multiple sclerosis 62 ascending doses 62 non nucleoside HCV 62 relapsing remitting MS RRMS 62 Pyridorin 62 Intravitreal 62 Panzem NCD 62 nonrandomized 62 regorafenib 62 treatment naive genotype 62 postoperative ileus POI 62 Vitaxin 62 IL# PE#QQR 62 oral Janus kinase 62 Tarceva TM 62 aldosterone antagonist 62 ongoing Phase 1b 62 TPI ASM8 62 CIMZIA TM 62 delafloxacin 62 Dose Ranging Study 62 TBC# 62 severe gastroparesis 62 plus prednisone prednisolone 62 Combo Stent 62 RE LY ® 62 investigational protease inhibitor 62 ThermoDox R 62 ENMD # 62 Omacetaxine 62 Eluting Stent 62 targeted antifolate 62 Solid Tumors 62 PRoFESS 62 dose cohort 62 varespladib 62 PEGPH# 62 antitumor effect 62 rifalazil 61 liposome encapsulated 61 CYP#A# CYP#D# 61 Mg Uk 61 Natalizumab 61 phase IIIb 61 radezolid 61 Clinical Trial Results 61 DG# compounds targeting 61 Imprime PGG 61 generation NNRTI 61 sunitinib Sutent ® 61 Initiates Enrollment 61 PSN# [002] 61 Annamycin 61 treatment naïve genotype 61 rALLy clinical trial 61 docetaxel Taxotere ® 61 chemotherapy FOLFOX 61 docetaxel chemotherapy 61 NPM1 mutation 61 Exelixis XL# 61 Alocrest 61 microtubule inhibitor 61 midstage clinical 61 imetelstat 61 oral antiviral 61 oral picoplatin 61 retaspimycin 61 Cannabinor 61 INCB# [003] 61 multicentre randomized 61 non nucleoside inhibitor 61 pomalidomide 61 dose escalation phase 61 huC# DM4 61 somatostatin analog 61 MyVax R 61 masked placebo controlled 61 selective modulator 61 receptor inhibitor 61 maximally tolerated dose 61 Phase III multicenter 61 PrevOnco ™ 61 TLR antagonists 61 mg kg BID 61 farletuzumab 61 CD4 monoclonal antibody 61 LymphoStat B TM 61 Pivotal Phase III 61 hyperphenylalaninemia HPA due 61 IgG1 monoclonal antibody 61 CRLX# 61 rNAPc2 61 QUADRAMET R 61 Ganetespib 61 FDG PET imaging 61 platform HDL Mimetic 61 Phase #b/#a clinical 61 HGS# 61 NSABP B 61 Randomized Phase II 61 K ras mutations 61 mixed hyperlipidemia 61 prednisone prednisolone plus 61 Randomized Double Blind 61 evaluating picoplatin 61 Amrubicin 61 Efficacy endpoints 61 product platforms AZX# 61 ENL recurrence 61 ZOLINZA 61 Clinical Antipsychotic Trials 61 hypoxia selective 61 Phase 2b Trial 61 MCSP respectively 61 Darusentan 61 STRATEGY FOR AN OPEN 61 Antiviral Activity 61 OncoVEX GM CSF 61 ALN TTR# 61 budesonide foam 61 iobenguane 61 CDK inhibitor 61 humanized therapeutic 61 Pegasys ® 61 CCX# B 61 generation purine nucleoside 61 TRAIL R1 61 Methylnaltrexone 61 R#/MEM # 61 MYCAMINE 61 LungAlert TM 61 Sym# 61 CD# CEA 61 IMiDs 61 cyclophilin inhibitor 61 Tolvaptan 61 AVOREN 61 targeted radiotherapeutic 61 receptor tyrosine kinase inhibitor 61 PRT# 61 antiplatelet therapies 61 Darinaparsin 61 melphalan prednisone 61 antibody MAb 61 Zenvia ™ 61 genotoxicity 61 Intervention Effectiveness 61 low dose cytarabine 61 MEND CABG 61 dexamethasone Decadron 61 HepDirect prodrug 61 cytoreductive nephrectomy 61 preclinical xenograft models 61 CK # administered 61 intravenous methylnaltrexone 61 Pharmacokinetic PK 61 Immunomodulatory 61 Trial Evaluating 61 class mGluR5 inhibitor 61 PEG SN# 61 paclitaxel poliglumex 61 metastatic neuroendocrine tumors 61 Phase IIA 61 aflibercept VEGF Trap 61 sargramostim 61 orally administered inhibitor 61 EOquin TM 61 Pharmacokinetic studies 61 CTA# Injection 61 MKC# MT 61 viral kinetic 61 oral Azacitidine 61 Study Evaluating 61 pralatrexate injection folate analogue 61 placebo controlled Phase 61 Pivotal Phase 61 2 methoxyestradiol 61 mecamylamine 61 ONCONASE R 61 immunotherapeutic approaches 61 YONDELIS 61 highly selective endothelin 61 Tolerability 61 leukemia AML 61 Folfox 61 endothelin antagonist 61 PHX# 61 weekly subcutaneous injections 61 diarrhea predominant irritable 61 Anti Tumor 61 xenograft models 61 multicenter randomized controlled 61 metastatic castration resistant 61 cMET 61 Secondary endpoints 61 TRIOLEX HE# APOPTONE HE# 61 Aplidin R 61 mGluR2 NAM 61 Peginterferon 61 Myocardial Perfusion Imaging 61 flavopiridol 61 multicenter multinational 61 nucleoside naive 61 RECORD1 61 Aplidin 61 idarubicin 61 uricase 61 refractory metastatic 61 Nebulized 61 Angiotensin Converting Enzyme 61 Phase Ib 61 ADMIRE HF 61 Trastuzumab DM1 61 eprotirome 61 GMX# 61 Posiphen 61 Multimeric 61 RSD# oral 61 phase IIb clinical 61 prospective multicentre 61 Lubiprostone 61 Pharmacokinetic 61 Xeloda ® 61 induced macular edema 61 LAB CGRP 61 papillary renal cell carcinoma 61 busulfan 61 indibulin 61 Phase #/#a clinical 61 Naive Patients 61 Pegylated Interferon 61 BFPET 61 Phase IIb randomized 61 including eniluracil ADH 61 myocardial infarction ventricular fibrillation 61 gemcitabine Gemzar 61 Daclizumab 61 recombinant PSMA vaccine 61 pan HDAC inhibitor 61 prucalopride 61 aplindore 61 visilizumab 61 GSK# [002] 61 Pazopanib 61 tumor xenograft models 61 intravesical instillation 61 PDX pralatrexate 61 inhibitor RG# 61 Epidermal Growth Factor Receptor 61 Long Term Efficacy 61 lomitapide 61 Myelofibrosis 61 HCV SPRINT 61 aspirin clopidogrel 61 cetuximab Erbitux R 61 TOCOSOL Camptothecin 61 APPRAISE 61 orally inhaled 61 biliary tract cancer 61 PRTX 60 phase IIa clinical 60 daily Infergen 60 IMiDs ® 60 Personalized Immunotherapy 60 SinuNase ™ 60 vitro cytotoxicity 60 ulimorelin 60 Relapsing Multiple Sclerosis 60 combines bupropion 60 Phase 2a Clinical Trial 60 Blinatumomab 60 gastro intestinal inflammation 60 Iloperidone 60 Phase 1a clinical 60 Parathyroid Hormone 60 Microplasmin 60 Initiate Clinical Trial 60 Pimavanserin 60 Antitumor Activity 60 Phase IIIb clinical 60 dose escalation Phase 60 candidates Azedra TM 60 Spiegelmer ® 60 acadesine 60 pharmacogenetic tests 60 prospectively randomized 60 PRE SURGE 60 TMC# C# 60 Trofex 60 ASPIRE HIGHER 60 dexpramipexole 60 dosing regimens 60 trastuzumab Herceptin ® 60 placebo controlled randomized 60 Budesonide foam crofelemer 60 pharmacokinetic characteristics 60 orally bioavailable 60 optimal dosing 60 BAY #-# 60 azilsartan medoxomil 60 Vascugel 60 bortezomib Velcade 60 APTIVUS r 60 modified glutathione analog 60 See CLINICAL PHARMACOLOGY 60 EURIDIS 60 corticosteroid dexamethasone 60 TACI Ig 60 refractory NSCLC 60 sapacitabine CYC# 60 pharmacokinetic interactions 60 controlled multicenter 60 Myocet 60 ELACYT 60 rheumatoid arthritis psoriatic arthritis 60 systemic RNAi therapeutic 60 BoNTA 60 candidate CRLX# 60 dose limiting toxicities 60 Vandetanib 60 pan histone deacetylase 60 Tasigna prolongs 60 phase IIb 60 Aurora Kinase 60 icatibant 60 RRM1 60 metastatic androgen independent 60 Kahalalide F 60 immunohistochemical staining 60 Phase 1b trial 60 Initiates Clinical 60 optimal dosing regimens 60 Tarvacin TM 60 Tyrima 60 Cloretazine ® 60 Xelox 60 JAK Inhibitor 60 Proc Am Soc 60 recurrent malignant glioma 60 stated Michelle Berrey 60 Protease Inhibitor 60 angiotensin analog 60 peginterferon alpha 2a 60 hematopoietic cancers 60 microsphere therapy 60 zonisamide SR 60 cardio renal 60 ATRA IV 60 APTIVUS 60 prospective multicenter randomized 60 Proellex TM 60 metastatic malignant 60 differentiate squamous 60 coronary stent merged 60 thymalfasin 60 Fulvestrant 60 Telik logo TELINTRA 60 antiangiogenic agent 60 ritonavir boosted danoprevir 60 aerosolized AAT 60 prospective randomized placebo 60 dose dose escalation 60 SYNTAX trial 60 talabostat 60 prospective randomized controlled 60 exploratory endpoints 60 cancer neuroendocrine tumor 60 hemodynamic measurements 60 JVRS 60 Azacitidine 60 randomized Phase 2b 60 Phase III placebo controlled 60 randomized multicenter 60 catheter occlusion 60 NOX E# 60 Forodesine HCl 60 Haptoglobin 60 dose escalation trial 60 motesanib 60 oral FTY# 60 Immunotherapeutic 60 vascular endothelial dysfunction 60 Ixempra 60 MVA MUC1 IL2 60 intravenous belinostat 60 seliciclib CYC# 60 Dabigatran etexilate 60 monoclonal antibody MAb 60 #:# randomization 60 tiuxetan 60 Omacetaxine mepesuccinate 60 invasive candidiasis 60 Symadex 60 Panzem R 60 myeloproliferative diseases 60 axitinib 60 azacytidine 60 posaconazole 60 SAR# [002] 60 histone deacetylase HDAC inhibitor 60 oral levofloxacin 60 Doxil ® 60 Squalamine 60 clevidipine 60 Presents Preclinical 60 recurrent NSCLC 60 efficacy 60 tipifarnib 60 reactogenicity 60 antidepressant efficacy 60 stage IIIb IV 60 serologically active systemic lupus 60 LEVADEX ™ 60 thalidomide Thalomid 60 R Saizen R 60 erythropoietic 60 estramustine 60 motesanib diphosphate 60 antiangiogenic activity 60 Zoraxel 60 Melphalan 60 lintuzumab 60 lintuzumab SGN 60 Thiovir 60 #/#/# Cytokinetics Incorporated 60 label multicenter Phase 60 DexaSite 60 efavirenz EFV 60 anti fibrotic 60 biostatistical analysis 60 CIMZIA R 60 ACTOS ® 60 trials RCTs 60 MEK Inhibitor 60 XL# XL# XL# 60 Nilotinib 60 alfa 2a 60 HMG CoA reductase inhibitors 60 intensive lipid lowering 60 Refractory Angina 60 Ribavirin causes 60 metastatic colorectal 60 Phase 2b Clinical Trial 60 Hedgehog Pathway Inhibitor 60 Combination REOLYSIN R 60 MEND CABG II 60 myeloproliferative disorders 60 placebo controlled multicenter 60 Kinoid 60 MTP inhibitor 60 INS# [001] 60 placebo controlled Phase III 60 EGFr expressing metastatic colorectal 60 CRMD# 60 rxRNA 60 vinorelbine tartrate 60 oral JAK#/JAK# inhibitor 60 anastrazole 60 ARB telmisartan 60 undergoing elective percutaneous 60 PITX2 methylation 60 XL# anticancer compounds 60 NSCLC tumors 60 Protein Kinase C 60 plus prednisone 60 agonistic human 60 orally dosed 60 Pegylated Liposomal Doxorubicin 60 nucleoside analog 60 confirmatory clinical 60 vitro pharmacology 60 antiangiogenic therapy 60 peptibody 60 Virulizin ® 60 MSI #F 60 adecatumumab 60 REG2 60 Prodarsan R 60 Septin9 biomarker 60 Intervention Effectiveness CATIE 60 randomized discontinuation 60 rhITF 60 locoregional 60 prospectively defined 60 intravesical 60 MiStent DES 60 Phase IIb Clinical Trial 60 refractory prostate cancer 60 oral gallium 60 acute mania 60 phase Ib clinical 60 radiation sensitizer 60 reslizumab 60 multicenter Phase 60 GORE VIABAHN Endoprosthesis 60 pegylated liposomal doxorubicin 60 oral dnaJP1 60 Acute Ischemic Stroke 60 subcutaneous formulation 60 intranasal delivery 60 Preclinical Study 60 MAbs targeting 60 intradermal injections 60 patients undergoing percutaneous 59 keloid scarring 59 #F FDG PET 59 unfractionated heparin UFH 59 Mitoxantrone 59 SSc 59 Nexavar sorafenib tablets 59 Elotuzumab 59 daunorubicin 59 Multivariate logistic regression 59 hepatic lesions 59 lucinactant 59 MoxDuo TM IR 59 ADP receptor antagonist 59 observational cohort 59 antithrombotic agents 59 MKC# MKC# PP 59 haematologic 59 Bioavailability 59 Demonstrates Positive 59 Bezielle 59 8mg/kg 59 Matrix Phase 2b 59 PNP inhibitor 59 Sanofi Pasteur Fluzone 59 opioid induced bowel dysfunction 59 GVAX Pancreas Vaccine 59 secondary efficacy endpoints 59 oxypurinol 59 Tocilizumab 59 HuLuc# 59 Immunogenicity 59 endophenotypes 59 predictive biomarkers 59 hematological parameters 59 Glatiramer Acetate 59 Decitabine 59 XmAb# 59 specific CCR9 antagonist 59 ALN PCS 59 orally bioavailable mimics 59 selective inhibition 59 DU #b 59 inhaled iloprost 59 albiglutide 59 CA9 SCAN 59 PURE proprietary 59 PEGylated Fab fragment 59 PROSTASCINT R 59 Interferon beta 1a 59 Placebo Controlled Trial 59 primary hypercholesterolemia 59 GEM OS2 59 novel chimeric natriuretic 59 PEGylated anti 59 somatostatin analogue 59 Pralatrexate 59 small molecule thrombopoietin 59 ganetespib 59 ocular formulation 59 Empatic ™ 59 herpetic keratitis 59 Achieves Primary Endpoint 59 Secondary efficacy endpoints 59 Controlled Trial 59 Genasense ® oblimersen 59 Diabetic Foot Ulcer 59 Entereg TM 59 TAXUS V 59 Elvitegravir 59 Locked Nucleic Acid LNA 59 Presents Preclinical Data 59 EFAPROXYN 59 vivo preclinical 59 Vascular Disrupting Agent 59 relapsed refractory multiple myeloma 59 BR.# 59 OHR/AVR# 59 Darapladib 59 HIF PHI 59 OBJECTIVES 59 TASKi2 59 compound AEZS 59 lorvotuzumab mertansine 59 tigecycline 59 volociximab 59 label multicenter 59 abacavir lamivudine 59 MET amplification 59 cytotoxic effects 59 Fondaparinux 59 dosage regimens 59 PROCHYMAL 59 drug zotarolimus 59 gp# vaccine 59 CINTREDEKIN BESUDOTOX 59 including cyclosporine methotrexate 59 SUTENT ® 59 basal bolus regimen 59 methylnaltrexone bromide 59 ® bortezomib 59 antitumor activity 59 pegylated interferon alfa 2b 59 GetGoal Phase III 59 dosing cohort 59 ExTRACT TIMI 59 tumor hypoxia 59 idraparinux 59 Lisofylline LSF 59 polycythemia vera PV 59 DASISION 59 XL# SAR# 59 BAL# [002] 59 BRIM3 59 prospective multicenter study 59 kinase inhibition 59 sodium thiosulfate STS 59 peripherally acting 59 TransVax TM 59 Prolongs Survival 59 Second Pivotal Phase 59 candesartan cilexetil